Ovid Therapeutics (OVID) Competitors $0.33 +0.01 (+3.43%) As of 12:45 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock OVID vs. ZURA, ATOS, SNTI, OPTN, HLVX, EXOZ, OCX, CRBP, BDTX, and TCRXShould you be buying Ovid Therapeutics stock or one of its competitors? The main competitors of Ovid Therapeutics include Zura Bio (ZURA), Atossa Therapeutics (ATOS), Senti Biosciences (SNTI), OptiNose (OPTN), HilleVax (HLVX), Exozymes (EXOZ), OncoCyte (OCX), Corbus Pharmaceuticals (CRBP), Black Diamond Therapeutics (BDTX), and TScan Therapeutics (TCRX). These companies are all part of the "pharmaceutical products" industry. Ovid Therapeutics vs. Zura Bio Atossa Therapeutics Senti Biosciences OptiNose HilleVax Exozymes OncoCyte Corbus Pharmaceuticals Black Diamond Therapeutics TScan Therapeutics Zura Bio (NASDAQ:ZURA) and Ovid Therapeutics (NASDAQ:OVID) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, profitability and community ranking. Does the MarketBeat Community favor ZURA or OVID? Ovid Therapeutics received 335 more outperform votes than Zura Bio when rated by MarketBeat users. However, 79.31% of users gave Zura Bio an outperform vote while only 71.03% of users gave Ovid Therapeutics an outperform vote. CompanyUnderperformOutperformZura BioOutperform Votes2379.31% Underperform Votes620.69% Ovid TherapeuticsOutperform Votes35871.03% Underperform Votes14628.97% Does the media prefer ZURA or OVID? In the previous week, Zura Bio had 3 more articles in the media than Ovid Therapeutics. MarketBeat recorded 5 mentions for Zura Bio and 2 mentions for Ovid Therapeutics. Ovid Therapeutics' average media sentiment score of 1.29 beat Zura Bio's score of 1.28 indicating that Ovid Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Zura Bio Positive Ovid Therapeutics Positive Is ZURA or OVID more profitable? Zura Bio has a net margin of 0.00% compared to Ovid Therapeutics' net margin of -5,142.56%. Zura Bio's return on equity of -37.36% beat Ovid Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Zura BioN/A -37.36% -29.81% Ovid Therapeutics -5,142.56%-39.24%-26.19% Do insiders and institutionals have more ownership in ZURA or OVID? 61.1% of Zura Bio shares are held by institutional investors. Comparatively, 72.2% of Ovid Therapeutics shares are held by institutional investors. 22.1% of Zura Bio shares are held by insiders. Comparatively, 13.3% of Ovid Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has better valuation and earnings, ZURA or OVID? Ovid Therapeutics has higher revenue and earnings than Zura Bio. Zura Bio is trading at a lower price-to-earnings ratio than Ovid Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZura BioN/AN/A-$69.24M-$0.53-2.77Ovid Therapeutics$566K39.58-$52.34M-$0.38-0.83 Which has more volatility & risk, ZURA or OVID? Zura Bio has a beta of 0.08, suggesting that its stock price is 92% less volatile than the S&P 500. Comparatively, Ovid Therapeutics has a beta of 0.44, suggesting that its stock price is 56% less volatile than the S&P 500. Do analysts rate ZURA or OVID? Zura Bio currently has a consensus price target of $14.67, suggesting a potential upside of 897.73%. Ovid Therapeutics has a consensus price target of $3.03, suggesting a potential upside of 862.35%. Given Zura Bio's stronger consensus rating and higher probable upside, research analysts plainly believe Zura Bio is more favorable than Ovid Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zura Bio 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Ovid Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00 SummaryOvid Therapeutics beats Zura Bio on 9 of the 17 factors compared between the two stocks. Get Ovid Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OVID and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OVID vs. The Competition Export to ExcelMetricOvid TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$22.40M$6.85B$5.54B$7.93BDividend YieldN/A2.95%5.09%4.23%P/E Ratio-0.677.3222.6018.55Price / Sales39.58241.43400.01103.29Price / CashN/A65.8538.1834.62Price / Book0.256.486.774.25Net Income-$52.34M$143.41M$3.22B$248.18M7 Day Performance-9.14%1.91%1.10%0.91%1 Month Performance-7.29%4.28%2.48%2.58%1 Year Performance-89.73%-3.87%15.71%4.02% Ovid Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OVIDOvid Therapeutics4.4891 of 5 stars$0.33+3.4%$3.03+830.5%-89.7%$23.17M$566,000.00-0.6960Positive NewsGap UpZURAZura Bio3.1521 of 5 stars$1.41+2.9%$14.67+940.2%-64.6%$96.41MN/A-2.663Upcoming EarningsNews CoveragePositive NewsATOSAtossa Therapeutics1.9545 of 5 stars$0.74-1.8%$7.13+859.2%-44.9%$95.95MN/A-3.388SNTISenti Biosciences2.8659 of 5 stars$3.64-27.2%$10.00+174.7%-14.5%$94.66M$2.56M-0.234Upcoming EarningsAnalyst ForecastNews CoverageHigh Trading VolumeOPTNOptiNose3.2826 of 5 stars$9.34+0.6%$9.00-3.6%-31.1%$94.59M$78.23M-2.22190Short Interest ↓News CoveragePositive NewsHLVXHilleVax2.7637 of 5 stars$1.88+1.6%$3.00+59.6%-85.8%$94.27MN/A-0.6120Upcoming EarningsNews CoveragePositive NewsEXOZExozymesN/A$11.21+4.5%N/AN/A$93.81MN/A0.0029Gap UpOCXOncoCyte2.1733 of 5 stars$3.22-6.4%$4.42+37.2%+21.6%$92.09M$1.88M-0.73120CRBPCorbus Pharmaceuticals4.0284 of 5 stars$7.50-7.2%$59.13+688.3%-79.8%$91.74MN/A-1.6040Upcoming EarningsBDTXBlack Diamond Therapeutics3.5136 of 5 stars$1.60+0.6%$14.60+812.5%-71.2%$90.68MN/A-1.2090Upcoming EarningsNews CoveragePositive NewsTCRXTScan Therapeutics3.7624 of 5 stars$1.60flat$9.33+483.3%-82.0%$90.55M$2.82M-1.51100Positive News Related Companies and Tools Related Companies ZURA Alternatives ATOS Alternatives SNTI Alternatives OPTN Alternatives HLVX Alternatives EXOZ Alternatives OCX Alternatives CRBP Alternatives BDTX Alternatives TCRX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OVID) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeWhile everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ovid Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ovid Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
